Holly Michelle Holmes

Holly Michelle Holmes

Auto-generated profile, based on publicly available information

Holly Michelle Holmes

The University of Texas MD Anderson Cancer Center, Houston, TX

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Journal of Geriatric Oncology
Verified
Journal Article
Open access
MSManvi Sharma
Manvi Sharma
KLKah Poh Loh
Kah Poh Loh
GNGinah Nightingale
Ginah Nightingale
SMSupriya G. Mohile
Supriya G. Mohile
HHHolly M. Holmes
Holly M. Holmes
Polypharmacy is a highly prevalent problem in older persons, and is challenging to assess and improve due to variations in definitions of the problem and the heterogeneous methods of medication review and reduction. The purpose of this review is to summarize evidence regarding the prevalence and impact of polypharmacy in geriatric oncology patients and to provide recommendations for assessment and management. Polypharmacy has somewhat variably been incorporated into geriatric assessment studies in geriatric oncology, and polypharmacy has not been consistently evaluated as a predictor of negative outcomes in patients with cancer. Once screened, interventions for polypharmacy are even more uncertain. There is a great need to create standardized interventions to improve polypharmacy in geriatrics, and particularly in geriatric oncology. The process of deprescribing is aimed at reducing medications for which real or potential harm outweighs benefit, and there are numerous methods to determine which medications are candidates for deprescribing. However, deprescribing approaches have not been evaluated in older patients with cancer. Ultimately, methods to identify polypharmacy will need to be clearly defined and validated, and interventions to improve medication use will need to be based on clearly defined and standardized methods.

2 April 2018 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
MSManvi Sharma
Manvi Sharma
AVAisha Vadhariya
Aisha Vadhariya
MJMichael L. Johnson
Michael L. Johnson
ZMZachary A. Marcum
Zachary A. Marcum
HHHolly M. Holmes
Holly M. Holmes
While many new medications may offer advantages over existing drugs, some newer drugs are reformulations of existing products that provide little innovation or incremental benefit while driving up drug costs. Despite the lack of benefit of these medications, prescribers may be motivated by payments made by the pharmaceutical industry. The objective of the study was to determine the association between payments made to physicians by the pharmaceutical industry and prescriptions for certain selected costly brand name drugs. This was a cross-sectional, retrospective study linking the Open Payments Database and Medicare Part D Prescriber Public Use File for 2014, including 667,278 physicians who prescribed one of 6 brand-name drugs with less costly but similarly effective alternatives: lovastatin ER, almotriptan, amlodipine+olmesartan, ibuprofen+famotidine, saxagliptin+metformin and naproxen+esomeprazole. The primary outcome was the odds of a physician prescribing one of the selected drugs, and the primary predictor was the receipt of any payment from the pharmaceutical industry. The odds of prescribing 3 of the 6 drugs were increased among physicians who received industry payment, compared to those without payment: amlodipine+olmesartan, aOR 1.42, (95% CI 1.36–1.49); saxagliptin+metformin, aOR 1.50, (95% CI 1.42–1.59); and naproxen+esomeprazole, aOR 1.45, (95% CI 1.25–1.68). Payment from the manufacturer of the specific drug, compared to not receiving payment from the drug’s manufacturer, was associated with increased odds of prescribing 4 of the 6 drugs: amlodipine+olmesartan, aOR 2.40, (95% CI 2.29–2.52), ibuprofen+famotidine, aOR 8.06, (95% CI 5.42–12.00), saxagliptin+metformin, aOR 2.21, (95% CI 2.10–2.34) and naproxen+esomeprazole, aOR 5.96, (95% CI 5.08–7.00). A physician-industry financial relationship was associated with increased odds of prescribing costly brand-name drugs of uncertain medical benefit. Patients, as healthcare consumers, should demand transparency from their physicians about payment from the pharmaceutical industry to increase shared decision-making. Physician and policy makers need increased awareness and reflection on how industry payment influences their prescribing practices.

1 May 2017 in Clinics in Geriatric Medicine
Verified
Journal Article
Open access
HHHolly M. Holmes
Holly M. Holmes
ATAdam Todd
Adam Todd
Polypharmacy and the use of inappropriate medications has become an increasing problem globally. Deprescribing has gained attention as a means to rationalize medication use. Deprescribing interventions have been shown to be generally feasible and safe; in the few studies in which patient preferences are assessed, such interventions also seem to be acceptable to patients. Qualitative studies suggest that patients are interested in reducing medications, may need education about their medications to facilitate deprescribing, and highly value communication with their providers around deprescribing. This article focuses on patient preferences for deprescribing and highlights practical recommendations to overcome barriers to deprescribing.

29 January 2016 in BMC Palliative Care
Verified
Journal Article
Open access
PDF file
ATAdam Todd
Adam Todd
HHHolly Holmes
Holly Holmes
SPSallie Pearson
Sallie Pearson
CHCarmel M Hughes
Carmel M Hughes
IAInga Andrew
Inga Andrew
AHAndy Husband
Andy Husband
There is a growing body of evidence suggesting patients with life-limiting illness use medicines inappropriately and unnecessarily. In this context, the perspective of patients, their carers and the healthcare professionals responsible for prescribing and monitoring their medication is important for developing deprescribing strategies. The aim of this study was to explore the lived experience of patients, carers and healthcare professionals in the context of medication use in life-limiting illness. In-depth interviews, using a phenomenological approach: methods of transcendental phenomenology were used for the patient and carer interviews, while hermeneutic phenomenology was used for the healthcare professional interviews. The study highlighted that medication formed a significant part of a patient’s day-to-day routine; this was also apparent for their carers who took on an active role-as a gatekeeper of care-in managing medication. Patients described the experience of a point in which, in their disease journey, they placed less importance on taking certain medications; healthcare professionals also recognize this and refer it as a ‘transition’. This point appeared to occur when the patient became accepting of their illness and associated life expectancy. There was also willingness by patients, carers and healthcare professionals to review and alter the medication used by patients in the context of life-limiting illness. There is a need to develop deprescribing strategies for patients with life-limiting illness. Such strategies should seek to establish patient expectations, consider the timing of the discussion about ceasing treatment and encourage the involvement of other stakeholders in the decision-making progress.

1 December 2015
Verified
Journal Article
Open access
PDF file
BKBeatriz Korc-Grodzicki
Beatriz Korc-Grodzicki
HHHolly M. Holmes
Holly M. Holmes
ASArmin Shahrokni
Armin Shahrokni
Geriatric assessment for oncologists

4 February 2019 in Drugs & Aging
Verified
Journal Article
Closed access
PDF file
MSManvi Sharma
Manvi Sharma
AVAisha Vadhariya
Aisha Vadhariya
SCSoumya Chikermane
Soumya Chikermane
SGSuma Gopinathan
Suma Gopinathan
MCMariana Chavez-MacGregor
Mariana Chavez-MacGregor
HHHolly M. Holmes
Holly M. Holmes